Clinical Trial Update: A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 study investigating the sequencing of pirtobrutinib after progression on first-line acalabrutinib in adults with chronic lymphocytic leukemia or small…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Pirtobrutinib (pirtobrutinib)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Status: WITHDRAWN